SEARCH

SEARCH BY CITATION

References

  • 1
    Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.
  • 2
    Schuurman HJ, Pall C, Weckbecker G, Schuler W, Bruns C. SDZ RAD inhibits cold ischemia-induced vascular remodelling. Transplant Proc 1999; 31: 1024.
  • 3
    Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation 2002; 106: 2379.
  • 4
    Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG, Kao PN. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respi Crit Care Med 2001; 163: 498.
  • 5
    Waksman R, Pakala R, Baffour R, et al. Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries. Cardiovasc Revasc Med 2006; 7: 179.
  • 6
    Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.
  • 7
    Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. On behalf of the 156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year Phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332.
  • 8
    Pascual J. Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors. Transplantation 2005; 79(Suppl. 9): S76.
  • 9
    Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008; 85: 821.
  • 10
    Salvadori M, Scolari MP, Bertoni E, et al. for the EVEREST Study Group. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009; 88: 1194.
  • 11
    Nankivell BJ, Borrrows RJ, Fung CL-S, O’Connell PJ, Allen RDM, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
  • 12
    Durrbach A, Rostaing L, Tricot L, et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 2008; 85: 486.
  • 13
    Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004; 15: 228.
  • 14
    Valente JF, Hricik D, Weigel K, et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003; 3: 1128.
  • 15
    Troppmann C, Pierce JL, Gandhi MM, Gallay BJ, McVicar JP, Perez RV. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 2003; 76: 426.
  • 16
    Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555.
  • 17
    Langer RM, Kahan BD. Incidence, therapy and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002; 74: 804.
  • 18
    Ekberg H, Tedesco-Silva H, Demirbas A, et al. ; for the ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
  • 19
    Schena FP, Pascoe MD, Alberu J, et al. Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
  • 20
    Holdaas H, Bentdal Ø, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008; 22: 366.
  • 21
    Budde K, Becker T, Sommerer C, et al. Analysis of renal function in everolimus/enteric-coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus study. Am J Transplant 2009; 9: 259. (Abstract 237).
  • 22
    Weir M, Mulgaonkar S, Pearson T, et al. Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2-year outcomes of the Spare-the-Nephron (STN) trial. Am J Transplant 2009; 9: 200. (Abstract 33).
  • 23
    Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009; 9: 1115.
  • 24
    Pietruck F, Klempnauer J, Arns W, et al. Efficacy and safety of everolimus (RAD)/enteric-coated mycophenolate sodium (EC-MPS) after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final results of the ZEUS trial. Am J Transplant 2009; 9: 259. (Abstract 1093).
  • 25
    Tedesco-Silva H Jr, Vitko S, Pascual J, et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007; 20: 27.
  • 26
    Tedesco-Silva H, Kim YS, Lackova E, et al. Everolimus with reduced-dose cyclosporine: results from a randomized study in 833 de-novo renal-transplant recipients. Transpl Int 2009; 22: 186.
  • 27
    Bertoni E, Larti A, Farsetti S, et al. Cyclosporine (CyA) very low dose with everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment with EC-MPS (M). Transpl Int 2009; 22: 91.
  • 28
    Gaber AO, Kahan BD, Van Buren C, et al. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. Transplantation 2008; 86: 1187.
  • 29
    Albano L, Berthoux F, Moal M-C, Rostaing L, Legendre C, Genin R. Incidence of delayed graft function and wound healing complications following deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009; 88: 69.
  • 30
    Nankivell BJ, Gruenewald SM, Allen R, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.
  • 31
    Nankivell BJ, Borrows RJ, Fung CL-S, O’Connell PJ, Chapman JR, Allen RDM. Calcineurin nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
  • 32
    Barsoum RS, Morsey AA, Iskander IR, et al. The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes. Exp Clin Transplant 2007; 5: 649.
  • 33
    Boratynska M, Banasik M, Patrzalek D, Klinger M. Impact of sirolimus treatment in kidney allograft recipients with prolonged cold ischemia times: 5-year outcomes. Exp Clin Transplant 2008; 6: 59.
  • 34
    Chang GJ, Mahanty HD, Vincenti F, et al. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant 2000; 14: 550.
  • 35
    Tiong HY, Flechner SM, Zhou L, et al. A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients. Transplantation 2009; 87: 296.
  • 36
    Margreiter R, Vitko S, Whelchel J, et al. Comparable incidence and severity of wound-healing-associated complications in the presence of MMF or everolimus following renal transplantation. Am J Transplant 2009; 9: 201. (Abstract 34).
  • 37
    Goel M, Flechner SM, Zhou L, et al. The influence of various maintenance immunosuppressive drugs on lymphocele formation and treatment after kidney transplantation. J Urol 2004; 171: 1788.
  • 38
    Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43: 83.
  • 39
    Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521.
  • 40
    Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003; 349: 847.